Consistently, preliminary data from Gartung et al. reported that, in a murine model of head and neck cancer, resolvins and immune checkpoint inhibitors (e.g., anti-PD-1) act synergistically, by suppressing tumor growth [63]. Here, PDCD1 is linked to neoplasm.